Product Center
The First Phase of The Vaccine Industrialization Project Was Successfully Completed
- Categories:Industry news
- Author:
- Origin:
- Time of issue:2017-08-30
- Views:
(Summary description)The human vaccine industrialization project of Ab&B Bio-Tech Co., Ltd. (JS) covers an area of 70 acres (approx. 46,666 square meters), with a planned construction area of 50,000 square meters. The first-phase construction projects include: an R&D complex building, production workshop No. 1, an animal room, and a central laboratory.
The First Phase of The Vaccine Industrialization Project Was Successfully Completed
(Summary description)The human vaccine industrialization project of Ab&B Bio-Tech Co., Ltd. (JS) covers an area of 70 acres (approx. 46,666 square meters), with a planned construction area of 50,000 square meters. The first-phase construction projects include: an R&D complex building, production workshop No. 1, an animal room, and a central laboratory.
- Categories:Industry news
- Author:
- Origin:
- Time of issue:2017-08-30 10:57
- Views:
The human vaccine industrialization project of Ab&B Bio-Tech Co., Ltd. (JS) covers an area of 70 acres (approx. 46,666 square meters), with a planned construction area of 50,000 square meters. The first-phase construction projects include: an R&D complex building, production workshop No. 1, an animal room, and a central laboratory. The single-building facility, with a total area of 30,000 square meters, was successfully completed on August 30, 2017, and then entered the stage of interior decoration and process construction to prepare for clinical trials in 2018.
Relevant information
-
Phase I/II Clinical Trial of the Re engineered Respiratory Syncytial Virus Vaccine (CHO Cells)(Adjuvant)Officially LaunchedOn May 13, the launch meeting for the Phase I/II clinical trial of the recombinant respiratory syncytial virus vaccine (CHO cell-based) (adjuvant) independently developed by Ab&B Bio-Tech CO.,LTD.JS. (Ab&B Bio) was successfully held at the research site in Sichuan. - The mRNA technology platform has achieved another milestone, with global innovation efforts accelerating. 05-08
- Our innovative vaccine research team won the 20th "Jiangsu Youth May Fourth Medal Collective" award 04-27
- The Ab&B Bio Promotion Business Conference and 10th Anniversary Celebration were successfully held 04-25
- Steadily promoting national recruitment and supplementation standards, the first and only trivalent influenza virus subunit vaccine for the entire population helps global 2026 influenza prevention and control! 04-14
Got a project? Contact us today !
At Ab&B Bio, our mission is to care for life and protect health by developing globally innovative vaccines.
Contact
E-mail:haixin.zhang@yitherbiotech.com
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us
